Trials / Completed
CompletedNCT02279966
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vortioxetine 10 mg | |
| DRUG | Paroxetine 20 mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-10-31
- Last updated
- 2017-02-28
Locations
18 sites across 4 countries: Estonia, Finland, Germany, Lithuania
Source: ClinicalTrials.gov record NCT02279966. Inclusion in this directory is not an endorsement.